22nd Century Group, Inc. (XXII): Price and Financial Metrics
XXII Price/Volume Stats
Current price | $0.91 | 52-week high | $21.75 |
Prev. close | $0.95 | 52-week low | $0.91 |
Day low | $0.91 | Volume | 229,900 |
Day high | $0.99 | Avg. volume | 593,196 |
50-day MA | $2.15 | Dividend yield | N/A |
200-day MA | $9.01 | Market Cap | 19.22M |
XXII Stock Price Chart Interactive Chart >
XXII POWR Grades
- Momentum is the dimension where XXII ranks best; there it ranks ahead of 75.31% of US stocks.
- The strongest trend for XXII is in Value, which has been heading up over the past 177 days.
- XXII's current lowest rank is in the Quality metric (where it is better than 0.33% of US stocks).
XXII Stock Summary
- As for revenue growth, note that XXII's revenue has grown 113.72% over the past 12 months; that beats the revenue growth of 95.36% of US companies in our set.
- In terms of volatility of its share price, XXII is more volatile than 96.27% of stocks we're observing.
- 22ND CENTURY GROUP INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -232.06%, greater than the shareholder yield of just 2.7% of stocks in our set.
- Stocks that are quantitatively similar to XXII, based on their financial statements, market capitalization, and price volatility, are VEEE, AYTU, XERS, XGN, and CREX.
- XXII's SEC filings can be seen here. And to visit 22ND CENTURY GROUP INC's official web site, go to www.xxiicentury.com.
XXII Valuation Summary
- In comparison to the median Consumer Defensive stock, XXII's EV/EBIT ratio is 102.89% lower, now standing at -0.5.
- Over the past 154 months, XXII's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for XXII.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
XXII | 2023-09-22 | 0.3 | 0.3 | -0.3 | -0.5 |
XXII | 2023-09-21 | 0.3 | 0.3 | -0.3 | -0.5 |
XXII | 2023-09-20 | 0.3 | 0.3 | -0.3 | -0.5 |
XXII | 2023-09-19 | 0.3 | 0.4 | -0.3 | -0.5 |
XXII | 2023-09-18 | 0.3 | 0.4 | -0.3 | -0.5 |
XXII | 2023-09-15 | 0.3 | 0.4 | -0.4 | -0.6 |
XXII Growth Metrics
- Its year over year price growth rate is now at -57.21%.
- The 3 year net income to common stockholders growth rate now stands at -219.42%.
- Its 3 year net cashflow from operations growth rate is now at -38.56%.

The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 50.865 | -37.28 | -47.483 |
2022-06-30 | 39.293 | -30.321 | -43.821 |
2022-03-31 | 33.187 | -26.856 | -36.497 |
2021-12-31 | 30.948 | -22.839 | -32.609 |
2021-09-30 | 30.296 | -21.204 | -25.048 |
2021-06-30 | 29.795 | -16.418 | -19.829 |
XXII's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XXII has a Quality Grade of F, ranking ahead of 0.97% of graded US stocks.
- XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
- MO, TPB, and PM are the stocks whose asset turnover ratios are most correlated with XXII.
The table below shows XXII's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.448 | 0.073 | -0.387 |
2021-03-31 | 0.485 | 0.065 | -0.480 |
2020-12-31 | 0.479 | 0.051 | -0.435 |
2020-09-30 | 0.446 | 0.038 | -0.388 |
2020-06-30 | 0.425 | 0.025 | -0.494 |
2020-03-31 | 0.400 | 0.015 | -0.537 |
XXII Price Target
For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $6.33 | Average Broker Recommendation | 1.5 (Moderate Buy) |
22nd Century Group, Inc. (XXII) Company Bio
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.
Latest XXII News From Around the Web
Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.
22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five StatesFirst Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced its FDA authorized VLN® reduced nicotine content cigarettes designed specifically to promote tobacco h |
Presenting on the Emerging Growth Conference on September 6 and 7 Register NowMIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting com |
22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco AssetsBUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company’s tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements, |
22nd Century Group, Inc. (NASDAQ:XXII) Analysts Just Slashed This Year's Revenue Estimates By 11%The latest analyst coverage could presage a bad day for 22nd Century Group, Inc. ( NASDAQ:XXII ), with the analysts... |
Adobe upgraded, BorgWarner downgraded: Wall Street's top analyst callsAdobe upgraded, BorgWarner downgraded: Wall Street's top analyst calls |
XXII Price Returns
1-mo | -48.59% |
3-mo | -82.64% |
6-mo | -92.11% |
1-year | -93.53% |
3-year | -90.34% |
5-year | -97.84% |
YTD | -93.41% |
2022 | -70.21% |
2021 | 40.45% |
2020 | 100.00% |
2019 | -55.82% |
2018 | -11.07% |
Continue Researching XXII
Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...